Market Overview

Morgan Stanley Sees Johnson & Johnson Taking Rx Estimates Higher

Share:
Related JNJ
Benzinga's M&A Chatter for Thursday March 19, 2015
Lifetime Income Payments Or Lump Sum: How To Decide?
Johnson & Johnson: A Dividend Growth Powerhouse In The Making? (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Johnson & Johnson (NYSE: JNJ).

In the report, Morgan Stanley noted, “We're adjusting our pharma estimates modestly to reflect our changing market views and July sales and prescriptions data from IMS. Overall. we're taking our 2016 pharma sales estimates up by 3%, driving a 2% revision in EPS. The largest swing factors include Imbruvica and Invokana.”

Johnson & Johnson closed on Friday at $103.73.

Latest Ratings for JNJ

DateFirmActionFromTo
Mar 2015JefferiesMaintainsHold
Feb 2015JefferiesMaintainsHold
Jan 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (JNJ)

Around the Web, We're Loving...